Correlation Between SAB Biotherapeutics and Titan Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Titan Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Titan Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Titan Pharmaceuticals, you can compare the effects of market volatilities on SAB Biotherapeutics and Titan Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Titan Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Titan Pharmaceuticals.

Diversification Opportunities for SAB Biotherapeutics and Titan Pharmaceuticals

-0.47

Correlation Coefficient

SAB Biotherapeutics  Titan Pharmaceuticals

Very good diversification

The 3 months correlation between SAB and Titan is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Titan Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Titan Pharmaceuticals and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Titan Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Titan Pharmaceuticals has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Titan Pharmaceuticals go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Titan Pharmaceuticals

Given the investment horizon of 90 days SAB Biotherapeutics is expected to under-perform the Titan Pharmaceuticals. In addition to that, SAB Biotherapeutics is 1.43 times more volatile than Titan Pharmaceuticals. It trades about -0.13 of its total potential returns per unit of risk. Titan Pharmaceuticals is currently generating about 0.03 per unit of volatility. If you would invest  352.00  in Titan Pharmaceuticals on December 27, 2024 and sell it today you would lose (4.00) from holding Titan Pharmaceuticals or give up 1.14% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

SAB Biotherapeutics  vs.  Titan Pharmaceuticals

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Titan Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Titan Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent basic indicators, Titan Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with SAB Biotherapeutics and Titan Pharmaceuticals

The main advantage of trading using opposite SAB Biotherapeutics and Titan Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Titan Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Titan Pharmaceuticals will offset losses from the drop in Titan Pharmaceuticals' long position.

The idea behind SAB Biotherapeutics and Titan Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.